News & Updates
Filter by Specialty:
Two-dose hep-B vaccine more seroprotective than three-dose regimen in chronic liver disease patients
In a pooled post hoc analysis of three phase III trials, a novel two-dose hepatitis B (hep-B) vaccine regimen trumped the traditional three-dose regimen in inducing seroprotection in patients with chronic liver disease (CLD).
Two-dose hep-B vaccine more seroprotective than three-dose regimen in chronic liver disease patients
02 Dec 2021
PRO-C3 levels, ADAPT score accurately detect fibrosis in NAFLD
Plasma levels of PRO-C3, a serological biomarker for the detection of the formation of type III collagen, can act as a good indicator of disease activity and fibrosis in nonalcoholic fatty liver disease (NAFLD), a recent study has found.
PRO-C3 levels, ADAPT score accurately detect fibrosis in NAFLD
27 Nov 2021
Aspirin cuts HCC risk in CHB patients with heavy metabolic burden
Aspirin safely lowers the risk of hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients suffering from a heavy burden of metabolic risk, according to a study presented at The Liver Meeting Digital Experience 2021 of the American Association for the Study of Liver Diseases (AASLD 2021).